APGE.O

APGE.O has a strong liquidity position, as evidenced by a current ratio of 26.57, indicating that the company holds significantly more current assets than current liabilities. The company's cash and equivalents amount to $131.55 million, which is a substantial portion of its total assets of $937.13 million. The absence of long-term debt further supports the company's liquidity, with a debt-to-equity ratio of 0. In terms of profitability, APGE.O is currently unprofitable, with a net income of -$255.84 million and an operating income of -$285.59 million. The company's return on equity (ROE) is -28.3%, and its return on assets (ROA) is -27.3%, both significantly below the industry median for biotechnology firms. These negative returns suggest that the company is not generating sufficient returns to cover its cost of capital, which is a concern for investors. APGE.O's revenue is not segmented by geographic regions or product lines in the provided data, making it difficult to assess the company's geographic exposure or product diversification. However, the company's focus on healthcare diagnostics suggests that it may be exposed to market conditions in the healthcare sector, which is influenced by regulatory changes and technological advancements. The company's growth trajectory is uncertain, as it is currently experiencing negative operating and free cash flows. The operating cash flow is -$227.45 million, and the free cash flow is -$259.57 million. These negative cash flows indicate that the company is not generating enough cash to sustain operations without external financing. The capital expenditure of -$5.15 million suggests that the company is not investing heavily in new projects or infrastructure, which could limit its future growth potential. APGE.O's risk assessment indicates a low level of liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and the absence of long-term debt reduces the risk of financial distress. However, the company's negative net income and operating income suggest that it may face financial challenges in the future. The dilution potential is also low, as the number of shares outstanding is the same for both basic and diluted shares. Recent events and filings do not indicate any significant changes in the company's financial position or strategic direction. The company's price targets from analysts range from $82.00 to $160.00, with a mean price target of $118.31 and a median price target of $119.00. The mean recommendation from analysts is 1.72, indicating a generally positive outlook, with 8 strong-buy ratings, 7 buy ratings, and 3 hold ratings.